Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis

Arthritis Research and Therapy

Volumn 8, Issue 4, 2006, Pages

  Lequerré, Thierry ^a,b,c,d   Gauthier Jauneau, Anne Christine ^a,b,c   Bansard, Carine ^b,c   Derambure, Céline ^a,b,c   Hiron, Martine ^b,c,d   Vittecoq, Olivier ^a,b,c,d   Daveau, Maryvonne ^b,c,d,e   Mejjad, Othmane ^a   Daragon, Alain ^a   Tron, François ^b,c,d,e   Le Loët, Xavier ^a,b,c,d,e   Salier, Jean Philippe ^b,c,d,e  

^a ROUEN UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

^c UNIVERSITÉ DE ROUEN   (France)

^d Consortium EGERIE ^*  (France)

^e NONE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; INFLIXIMAB; MESSENGER RNA; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; BLOOD; DNA MICROARRAY; FEMALE; FOLLOW UP; GENE EXPRESSION PROFILING; HUMAN; MALE; METABOLISM; MIDDLE AGED; MONOCYTE; PREDICTIVE VALUE; TIME; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; HUMANS; MALE; MIDDLE AGED; MONOCYTES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PREDICTIVE VALUE OF TESTS; RNA, MESSENGER; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 43249100859     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar1990     Document Type: Article

References (46)

1. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, Genovese MC, Wasko MC, Moreland LW, Weaver AL, et al.: A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000, 343:1586-1593.
2. Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, Fischkoff SA, Chartash EK: Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumour necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004, 50 1400-1411.
3. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Furst D, Weisman MH, St Clair EW, Keenan GF, van der Heijde D, Marsters PA, Lipsky PE: Anti-tumour necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 2004, 50:1051-1065.
4. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, Martin Mola E, Pavelka K, Sany J, Settas L, et al.: Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: Double-blind randomised controlled trial. Lancet 2004, 363:675-681.
5. Smolen JS, Han C, Bala M, Maini RN, Kalden JR, van der Heijde D, Breedveld FC, Furst DE, Lipsky PE, ATTRACT Study Group: Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: A detailed subanalysis of data from the antitumour necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum 2005, 52:1020-1030.
6. den Broeder A, van de Putte L, Rau R, Schattenkirchner M, Van Riel P, Sander O, Binder C, Fenner H, Bankmann Y, Velagapudi R, et al.: A single dose, placebo controlled study of the fully human anti-tumour necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. J Rheumatol 2002, 29:2288-2298.
7. Ang HT, Helfgott S: Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumour necrosis factor-alpha antagonists in patients with rheumatoid arthritis? J Rheumatol 2003, 30:2315-2318.
8. Haraoui B, Keystone EC, Thorne JC, Pope JE, Chen I, Asare CG, Leff JA: Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept. J Rheumatol 2004, 31:2356-2359.
9. Lequerré T, Jouen F, Brazier M, Clayssens S, Klemmer N, Ménard J-F, Mejjad O, Daragon A, Tron F, Le Loët X, Vittecoq O: Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab Rheumatology 2006 in press.
10. Kang CP, Lee KW, Yoo DH, Kang C, Bae SC: The influence of a polymorphism at position -857 of the tumour necrosis factor alpha gene on clinical response to etanercept therapy in rheumatoid arthritis. Rheumatology 2005, 44:547-552.
11. Mugnier B, Balandraud N, Darque A, Roudier C, Roudier J, Reviron D: Polymorphism at position -308 of the tumour necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis. Arthritis Rheum 2003, 48:1849-1852.
12. Cuchacovich M, Ferreira L, Aliste M, Soto L, Cuenca J, Cruzat A, Gatica H, Schiattino I, Perez C, Aguirre A, et al.: Tumour necrosis factor-alpha (TNF-alpha) levels and influence of -308 TNFalpha promoter polymorphism on the responsiveness to infliximab in patients with rheumatoid arthritis. Scand J Rheumatol 2004, 33:228-232.
13. Mugnier B, Roudier J: Factors predicting responsiveness to anti-TNFα therapy in patients with rheumatoid arthritis: Using biotherapies rationally. Joint Bone Spine 2004, 71:91-94.
14. Lequerré T, Vittecoq O, Le Loët X: Comment about the editorial by Bénédicte Mugnier and Jean Roudier entitled "Factors predicting responsiveness to anti-TNFα therapy in patients with rheumatoid arthritis: Using biotherapies rationally". Joint Bone Spine 2005, 72:346-347.
15. Bridges SL Jr: Genetic markers of treatment response in rheumatoid arthritis. Arthritis Rheum 2004, 50:1019-1022.
16. Kekow J, Koczan D, Drynda S, Drynda A, Guthke R, Thiesen HJ: Early identification of responders to anti-TNFα therapy by microarrays technique [abstract]. Arthritis Rheum 2004:117.
17. Meisel C, Newton JL, Harney SM, Wordsworth BP, Brown MA: Gene expression profiling of treatment response to anti-TNFalpha therapy in rheumatoid arthritis [abstract]. Arthritis Rheum 2004:120.
18. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324.
19. van Gestel AM, Prevoo MLL, van't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL: Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. Arthritis Rheum 1996, 39:34-40.
20. Guillemin F, Braincon S, Pourel J: Measurement of the functional capacity in rheumatoid polyarthritis: A French adaptation of the Health Assessment Questionnaire (HAQ). Rev Rhum Mal Osteoartic 1991, 58:459-465.
21. Couloiuarn C, Lefebvre G, Derambure C, Lequerré T, Scotte M, François A, Cellier D, Daveau M, Salier JP: Altered gene expression in acute systemic inflammation detected by complete coverage of the human liver transcriptome. Hepatology 2004, 39 353-364.
22. Primer 3 [http://frodo.wi.mit.edu]
23. The R Project for Statistical Computing [http://www.rproject.org/]
24. TM4 Microarray Software Suite [http://www.tm4.org]
25. Tusher VG, R Tibshirani, Chu G: Significance analysis of microarrays applied to the ionizing radiation response. Proc Nat Acad Sci USA 2001, 98:5116-5121.
26. Gene Expression Omnibus [http://www.ncbi.nlm.nih.gov/ projects/geo]
27. Drynda S, Ringel B, Kekow M, Kuhne C, Drynda A, Glocker MO, Thiesen HJ, Kekow J: Proteome analysis reveals disease-associated marker proteins to differentiate RA patients from other inflammatory joint diseases with the potential to monitor anti-TNFalpha therapy. Pathol Res Pract 2004, 200:165-171.
28. Jarvis JN, Centola M: Gene-expression profiling: time for clinical application? Lancet 2005, 365:199-200.
29. Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Bijlsma JW, Dougados M, Emery P, Keystone EC, Klareskog L, Mease PJ: Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases. Ann Rheum Dis 2005, 64(Suppl 4):iV2-14.
30. Olsen NJ, Moore JH, Aune TM: Gene expression signatures for autoimmune disease in peripheral blood mononuclear cells. Arthritis Res Ther 2004, 6:120-128.
31. Allison DB, Cui X, Page GP, Sabripour M: Microarray data analysis: from disarray to consolidation and consensus. Nat Rev Genet 2006, 7:55-65.
32. Chen L, Borozan I, Feld J, Sun J, Tannis LL, Coltescu C, Heathcote J, Edwards AM, McGilvray ID: Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 2005, 128:1437-1444.
33. Lombardo F, Komatsu D, Hadjiargyrou M: Molecular cloning and characterization of Mustang, a novel nuclear protein expressed during skeletal development and regeneration. FASEB J 2004, 18 52-61.
34. Gao X, Fernandez-Vina M, Olsen NJ, Pincus T, Stastny P: HLADPB1· 0301 is a major risk factor for rheumatoid factor-negative adult rheumatoid arthritis. Arthritis Rheum 1991, 34:1310-1312.
35. Koch AE, Kunkel SL, Harlow LA, Mazarakis DD, Haines GK, Burdick MD, Pope RM, Walz A, Strieter RM: Epithelial neutrophil activating peptide-78: a novel chemotactic cytokine for neutrophils in arthritis. J Clin Invest 1994, 94:1012-1018.
36. Persson T, Monsef N, Andersson P, Bjartell A, Malm J, Calafat J, Egesten A: Expression of the neutrophil-activating CXC chemokine ENA-78/CXCL5 by human eosinophils. Clin Exp Allergy 2003, 33:531-537.
37. Chun YJ, Lee S, Yang SA, Park S, Kim MY: Modulation of CYP3A4 expression by ceramide in human colon carcinoma HT-29 cells. Biochem Biophys Res Commun 2002, 298:687-692.
38. Clausse N, van den Brule F, Delvenne P, Jacobs N, Franzen-Detrooz E, Jackers P, Castronovo V: TNF-alpha and IFN-gamma down-regulate the expression of the metastasis-associated bi-functional 37LRP/p40 gene and protein in transformed keratinocytes. Biochem Biophys Res Commun 1998, 251:564-569.
39. Hyc A, Osiecka-Iwan A, Strzelczyk P, Moskalewski S: Effect of IL-1beta, TNF-alpha and IL-4 on complement regulatory protein mRNA expression in human articular chondrocytes. Int J Mol Med 2003, 11:91-94.
40. Groettrup M, van den Broek M, Schwarz K, Macagno A, Khan S, de Giuli R, Schmidtke G: Structural plasticity of the proteasome and its function in antigen processing. Crit Rev Immunol 2001, 21:339-358.
41. Taberner M, Scott KF, Weininger L, Mackay CR, Rolph MS: Overlapping gene expression profiles in rheumatoid fibroblast-like synoviocytes induced by the proinflammatory cytokines interleukin-1 beta and tumour necrosis factor. Inflamm Res 2005, 54:10-16.
42. Zhou A, Scoggin S, Gaynor RB, Williams NS: Identification of NF-kappa B-regulated genes induced by TNFalpha utilizing expression profiling and RNA interference. Oncogene 2003, 22:2054-2064.
43. Tian B, Nowak DE, Jamaluddin M, Wang S, Brasier AR: Identification of direct genomic targets downstream of the nuclear factor-kappaB transcription factor mediating tumour necrosis factor signaling. J Biol Chem 2005, 280:17435-17448.
44. Schotte H, Schluter B, Drynda S, Willeke P, Tidow N, Assmann G, Domschke W, Kekow J, Gaubitz M: Interleukin 10 promoter microsatellite polymorphisms are associated with response to long term treatment with etanercept in patients with rheumatoid arthritis. Ann Rheum Dis 2005, 64:575-581.
45. O'Dell JR, Nepom BS, Haire C, Gersuk VH, Gaur L, Moore GF, Drymalski W, Palmer W, Eckhoff PJ, Klassen LW, et al.: HLADRB1 typing in rheumatoid arthritis: Predicting response to specific treatments. Ann Rheum Dis 1998, 57:209-213.
46. Nuki G, Bresnihan B, Bear MB, McCabe D, European Group Of Clinical Investigators: Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: Extension phase of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002, 46:2838-2846.